A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Status: Recruiting
Location: See all (5) locations...
Intervention Type: Biological
Study Type: Observational
SUMMARY
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Is at least 18 years of age and the local legal age of consent for clinical studies
• Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment
• If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening
Locations
United States
California
Profound Research LLC - Carlsbad
RECRUITING
Carlsbad
Florida
Visionary Investigators Network
RECRUITING
Miami
Maryland
Erlanger Health System
RECRUITING
Columbia
New York
Dent Neurologic Institute - Amherst
RECRUITING
Amherst
Texas
National Neuromuscular Research Institute
RECRUITING
Austin
Contact Information
Primary
Sabine Coppieters, MD
clinicaltrials@argenx.com
857-350-4834
Time Frame
Start Date: 2025-12-19
Estimated Completion Date: 2028-03-07
Participants
Target number of participants: 70
Treatments
ISA1 participants
Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Related Therapeutic Areas
Sponsors
Leads: argenx